Welcome to our dedicated page for Cerevel Therapeutics Hldng news (Ticker: CERE), a resource for investors and traders seeking the latest updates and insights on Cerevel Therapeutics Hldng stock.
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) is a clinical-stage biopharmaceutical leader pioneering neuroscience therapies for central nervous system disorders. This page serves as the definitive source for official company announcements, research milestones, and financial updates.
Investors and industry observers will find curated press releases covering clinical trial progress, regulatory developments, strategic partnerships, and quarterly results. Our aggregation ensures timely access to material information about CERE's neuropharmacology pipeline targeting Parkinson's, Alzheimer's, and schizophrenia.
All content is verified at source to maintain compliance with financial disclosure standards. Bookmark this page for streamlined tracking of Cerevel's advancements in receptor-specific therapies and neuroscience innovation.
Cerevel Therapeutics (Nasdaq: CERE) announced it will report its third quarter 2021 financial results on November 10, 2021, before U.S. markets open. Following the earnings report, management will host a conference call at 8:00 a.m. ET, accessible via phone and a live webcast on their investor website. Cerevel is focused on treating neuroscience diseases, with a diversified pipeline of five clinical-stage investigational therapies and pre-clinical compounds aimed at conditions like Parkinson’s, epilepsy, and schizophrenia.
Cerevel Therapeutics (Nasdaq: CERE) hosted a live R&D event on October 7, 2021, discussing key pipeline programs, including CVL-871 for dementia-related apathy and CVL-231 for schizophrenia. CVL-871 is in a Phase 2a trial, with results expected in H2 2022, and has received Fast Track designation from the FDA. CVL-231 has shown positive Phase 1b trial results and will progress to a Phase 2 development program. Both programs address significant unmet needs in neuroscience, with clinical experts contributing to the discussions.
Cerevel Therapeutics has announced the resignation of Kathy Yi as CFO, effective immediately, while Mark Bodenrader steps in as interim CFO. Yi, who will assist until November 15, 2021, departs to pursue personal interests. During her tenure, the company secured significant financing and strengthened its balance sheet. Cerevel focuses on neuroscience diseases and has a pipeline that includes therapies for schizophrenia, epilepsy, and Parkinson's disease. The company is currently searching for a permanent CFO.
Cerevel Therapeutics will hold a virtual R&D event on October 7, 2021, from 10:00 to 11:30 a.m. ET. The event will focus on CVL-871, a D1/D5 partial agonist for dementia-related apathy, and provide updates on CVL-231, an M4 positive allosteric modulator for schizophrenia. CVL-871 is in a Phase 2a trial with data expected in H2 2022. CVL-231 has shown positive results from its Phase 1b trial and will enter a comprehensive Phase 2 program. Access the live webcast on the Cerevel website, with replays available post-event.
Cerevel Therapeutics (Nasdaq: CERE) announced participation in two virtual investor conferences in September 2021. The events are the Citi 16th Annual BioPharma Virtual Conference on September 8, where Chief Medical Officer Raymond Sanchez will join an expert panel, and the Morgan Stanley 19th Annual Global Healthcare Conference on September 13, featuring a fireside chat with CEO Tony Coles. Live webcasts of these discussions will be available on their investor relations website, along with replays. Cerevel focuses on neuroscience diseases, with a diversified pipeline targeting conditions like schizophrenia and Parkinson's.
Cerevel Therapeutics announced positive topline results for CVL-231 in schizophrenia following its Phase 1b trial. The trial showed a statistically significant improvement in PANSS scores. The company raised $328 million in net proceeds from a follow-on offering and redeemed outstanding public warrants, bringing total capital raised to over $800 million. Cerevel also received Fast Track designation for CVL-871 in dementia-related apathy and initiated a Phase 2a trial. The company plans a virtual R&D update on October 7, 2021, highlighting its neuroscience pipeline and financial performance.
Cerevel Therapeutics announced plans to redeem all outstanding public warrants to purchase shares of its common stock on August 30, 2021, at 5:00 p.m. ET. Each public warrant can be exercised at a price of $11.50. Unexercised warrants will become void, with holders receiving a redemption price of $0.01. The redemption follows the company meeting the performance criteria for warrant redemption with common stock prices exceeding $18.00 for twenty trading days. The company has filed a registration statement for the shares underlying the warrants.
Cerevel Therapeutics (Nasdaq: CERE) announced it will report its second quarter 2021 financial results on August 11, 2021, before U.S. markets open. A conference call is scheduled for the same day at 8:00 a.m. EDT. Cerevel focuses on neuroscience diseases, with a diversified pipeline including five clinical-stage therapies targeting conditions like Parkinson's and epilepsy. The company emphasizes its commitment to unraveling brain mysteries, advancing R&D, and potential collaborations. Investors can access more information through the company's investor website.
Cerevel Therapeutics announced a public offering of 14,000,000 shares at $25.00 each, expected to yield approximately $350 million in gross proceeds. The closing is anticipated on July 7, 2021, contingent upon customary conditions. Underwriters have a 30-day option to buy an additional 2,100,000 shares. The offering aims to support the company's neuroscience initiatives, which target various diseases, including Parkinson's and schizophrenia. Major banks, including J.P. Morgan and Goldman Sachs, are managing the offering.
Cerevel Therapeutics (Nasdaq: CERE) has initiated an underwritten public offering of 14,000,000 shares of its common stock, with a potential 30-day option for underwriters to purchase an additional 2,100,000 shares. The offering is contingent on market conditions and no assurance can be provided regarding its completion. J.P. Morgan, Goldman Sachs, Jefferies, and Stifel serve as joint book-running managers. A registration statement was filed with the SEC but remains effective. The funds raised will potentially support Cerevel's pipeline in neuroscience therapies targeting conditions like Parkinson's and schizophrenia.
